Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Vatreptocog Alfa for Acute Bleeding in Hemophilia with Inhibitors
NCT01392547Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2011
- Primary completion
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of vatreptacog alfa in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Effective Bleeding Control Defined as no Additional Haemostatic Medication Given at 12 hours. Started Jul 2011; status: completed.
02
Drugs
vatreptacog alfa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT01392547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392547.